215 related articles for article (PubMed ID: 22147694)
1. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.
Gogna R; Madan E; Kuppusamy P; Pati U
J Biol Chem; 2012 Jan; 287(4):2907-14. PubMed ID: 22147694
[TBL] [Abstract][Full Text] [Related]
2. Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications.
Gogna R; Madan E; Kuppusamy P; Pati U
Cell Death Dis; 2012 Mar; 3(3):e286. PubMed ID: 22419115
[TBL] [Abstract][Full Text] [Related]
3. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
Xu J; Reumers J; Couceiro JR; De Smet F; Gallardo R; Rudyak S; Cornelis A; Rozenski J; Zwolinska A; Marine JC; Lambrechts D; Suh YA; Rousseau F; Schymkowitz J
Nat Chem Biol; 2011 May; 7(5):285-95. PubMed ID: 21445056
[TBL] [Abstract][Full Text] [Related]
4. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.
Blagosklonny MV
FASEB J; 2000 Oct; 14(13):1901-7. PubMed ID: 11023974
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia and hypoxia mimetic cooperate to counteract tumor cell resistance to glucose starvation preferentially in tumor cells with mutant p53.
Chavez-Perez VA; Strasberg-Rieber M; Rieber M
Biochem Biophys Res Commun; 2014 Jan; 443(1):120-5. PubMed ID: 24275138
[TBL] [Abstract][Full Text] [Related]
6. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
7. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
8. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
9. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
Wawrzynow B; Zylicz A; Zylicz M
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
[TBL] [Abstract][Full Text] [Related]
10. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.
Rivlin N; Katz S; Doody M; Sheffer M; Horesh S; Molchadsky A; Koifman G; Shetzer Y; Goldfinger N; Rotter V; Geiger T
Proc Natl Acad Sci U S A; 2014 May; 111(19):7006-11. PubMed ID: 24778235
[TBL] [Abstract][Full Text] [Related]
11. Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.
Okal A; Matissek KJ; Matissek SJ; Price R; Salama ME; Janát-Amsbury MM; Lim CS
Gene Ther; 2014 Oct; 21(10):903-12. PubMed ID: 25077773
[TBL] [Abstract][Full Text] [Related]
12. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
16. CHIP promotes autophagy-mediated degradation of aggregating mutant p53 in hypoxic conditions.
Maan M; Pati U
FEBS J; 2018 Sep; 285(17):3197-3214. PubMed ID: 29953728
[TBL] [Abstract][Full Text] [Related]
17. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
18. [Recent advances in mutant p53 and novel personalized strategies for cancer therapy].
Lu SQ; Jia ST; Luo Y
Yi Chuan; 2011 Jun; 33(6):539-48. PubMed ID: 21684858
[TBL] [Abstract][Full Text] [Related]
19. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
20. The oncofetal H19 RNA connection: hypoxia, p53 and cancer.
Matouk IJ; Mezan S; Mizrahi A; Ohana P; Abu-Lail R; Fellig Y; Degroot N; Galun E; Hochberg A
Biochim Biophys Acta; 2010 Apr; 1803(4):443-51. PubMed ID: 20117150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
